Market Minds Advisory
Sequestrants Market

Sequestrants Market: Biodegradable Chelate Adoption and the Pharmaceutical-Grade Shift

Sequestrants sit between a detergent and food preservation heritage built on EDTA-based chelation, and a biodegradable chelate shift pulling regulatory-conscious formulators toward alternatives that traditional persistent chelating agents cannot offer.

Lead Analyst

Lisa Gevelber

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$3.6BMarket Size 2025
2036 FORECAST VALUE$6.5BBase Case , 2026 to 2036
CAGR 2026 TO 20365.6 %Bull 6.8% / Bear 4.3%
INCREMENTAL OPPORTUNITY$2.8BNet 10- year value creation
EXPANSION MULTIPLE1.72x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Sequestrants built their commercial base on EDTA-based chelation for detergents and food preservation, and that chemistry still defines most of the category's volume today. Pharmaceutical and personal care grades are now the fastest-growing corners of the business, and regulatory pressure is driving that shift directly. Momentum keeps building.
Pharmaceutical and healthcare applications are growing fastest as drug stabilization and metal detox therapy formulators specify high-purity chelating agents that industrial-grade sequestrants cannot satisfy. Western Europe anchors global demand on its deep specialty chelating agent production heritage, while North America follows closely on water treatment and industrial descaling demand rather than pure detergent volume. That geographic split reflects production heritage as much as raw consumer demand.
Twenty companies compete across a market split between commodity EDTA-based sequestrants sold largely through established detergent and water treatment relationships, and biodegradable and pharmaceutical-grade products earning meaningfully more on formulation depth and regulatory documentation. Regulatory restrictions on persistent chelating agents genuinely complicate product planning in ways long-term industrial contracts cannot always fully absorb, and that exposure keeps widening for smaller regional producers over time. That widening gap defines competitive advantage now.
Market Definition
The market covers sequestrants and chelating agents used in food and beverage preservation, water treatment, detergents, personal care, pharmaceutical, and agricultural micronutrient applications. Unrelated metal complexing catalysts sold for industrial polymerisation processes are excluded from this scope.
Base Year Value
$3.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
5.6% base case. Bull 6.8%. Bear 4.3%.
Fastest Growth Segment
Pharmaceutical and Healthcare: 8.8% CAGR
Fastest Growth Country
India: 8.2% CAGR
Fastest Growth Region
South Asia and Pacific: 7.6% CAGR
Largest Region
Western Europe: 26% of 2025 global value
Market Leaders
Nouryon, BASF SE, Dow Inc, Lonza Group, Innophos Holdings. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Sequestrants Market Forecast Scenarios

sequestrants-market-report-trends-size-forecast-scenario-1787594607074
Between 2020 and 2025 the market grew near 4.8% a year, held back by tightening EU regulatory restrictions on persistent chelating agents before biodegradable chelate and pharmaceutical-grade demand began contributing meaningfully toward the end of the historical period, a shift that strengthened once reformulation cycles completed. Manufacturer reformulation cycles have since normalised, restoring more predictable annual growth across most developed markets.
The base case carries the market to 5.6% CAGR on three mechanisms: water treatment and industrial descaling demand expanding across growing industrial and municipal infrastructure, food safety regulation driving preservative-grade sequestrant adoption in emerging markets, and pharmaceutical-grade chelate demand accelerating alongside drug stabilization and metal detox therapy development. None of these three mechanisms depends on any single end-use category recovering alone, which is what makes the base case durable across regulatory and consumer spending cycles.
The bull case at 6.8% assumes faster biodegradable chelate adoption across major detergent manufacturers than currently modelled. The bear case at 4.3% assumes continued regulatory restriction on persistent chelating agents outweighs biodegradable and pharmaceutical-grade growth by a wider margin than currently anticipated, leaving overall category volume flatter than the base case projects. Neither scenario depends on any single national regulatory timeline alone.

EDTA Heritage Meets the Biodegradable Pull

Three forces shape this market at once, and each moves on its own separate timeline. EDTA-based volume tracks detergent and food preservation demand cycles set years in advance, biodegradable chelate demand tracks tightening environmental regulation largely independent of those established cycles, and pharmaceutical-grade demand tracks drug development timelines disconnected from either commercial driver.
EDTA-BASED APPLICATION SHARE38%share of volume still using traditional EDTA-based chelation
AVERAGE SELLING PRICEUSD 3.60/kgblended price across commodity and specialty grades sold
TOP PRODUCER SHARE15%largest single producer share of category chemical revenue
METAL BINDING CAPACITY RANGE0.3 to 0.5 mol/moltypical metal binding capacity range across chelate types
FEEDSTOCK COST SHARE42%share of production cost from key feedstock inputs
HHI CONCENTRATION620a moderately concentrated category with regional specialty chemical scale
Commercially, the market behaves like a specialty pharmaceutical-adjacent chemical business wearing a commodity additive label. Purity documentation genuinely matters, since pharmaceutical and personal care applications depend on documented trace-metal specification that buyers scrutinise closely during qualification, but adoption still tracks delivered cost and regulatory compliance more than pure chelation chemistry alone. A producer with strong biodegradability credentials competes on regulatory trust long before it competes on price.
Over the next decade, biodegradable and pharmaceutical-grade demand will decide winners more than EDTA-based volume alone, since EDTA demand already tracks a well-established, regulation-constrained consumption cycle. Companies investing early in biodegradable chelate chemistry will capture growth that EDTA-only producers cannot easily replicate without significant reformulation investment. Later movers will find catching up considerably more expensive once that formulation gap compounds. Later movers will find catching up considerably more expensive once that gap compounds further.
"EDTA built this category for half a century. Every reformulation conversation happening in Europe right now starts with what replaces it, not whether to replace it."
Director, Specialty Chelating Agents and Food Chemistry Practice · MMA Chemicals and Materials Practice · August 2026

Market Trends

Biodegradable Chelate Chemistry Reshapes Product Development

Detergent and personal care formulators increasingly specify biodegradable chelating agents such as GLDA and MGDA in place of traditional EDTA, a reformulation challenge that legacy production processes were never designed to solve at comparable metal binding performance and cost. This trend reaches an entirely different regulatory conversation than traditional EDTA renewal, spanning environmental compliance teams investing at a pace conventional additive demand rarely matches. Producers with dedicated biodegradable chemistry capability are capturing this demand fastest, since achieving comparable chelation performance in readily biodegradable molecules requires meaningful research investment most EDTA-focused producers have not committed to.
Market Impact: Adds USD 52 million by 2029

Pharmaceutical-Grade Chelate Demand Expands Beyond Industrial Use

Pharmaceutical manufacturers increasingly specify high-purity chelating agents for drug stabilization and metal detoxification therapy formulations, a purity requirement that industrial-grade sequestrant production was never designed to satisfy at pharmacopoeia documentation standards. Producers investing in dedicated pharmaceutical-grade purification and quality systems are capturing this specification shift specifically, since standard industrial-grade material carries broader impurity tolerance than these applications now require. This shift is gradually changing how established producers structure quality system investment. Buyers increasingly request documented trace-metal testing before finalising annual purchase agreements with any single supplier. Formulation science teams increasingly work alongside marketing to validate biodegradability claims before launch.
Market Impact: Adds USD 38 million by 2030

Market Opportunities and Growth Drivers

Water Treatment Demand Expands Industrial Descaling Applications

Industrial and municipal water treatment facilities continue expanding descaling and scale-inhibition chemical programs as aging infrastructure and tightening water quality standards drive demand for effective metal ion management. Water treatment operators increasingly favour sequestrant-based descaling programs over mechanical alternatives given the operational continuity and cost advantage this represents relative to physical descaling downtime. This demand base provides a stable multi-year foundation even as broader industrial capital spending fluctuates with interest rates and infrastructure budget cycles. Producers with early water utility relationships in these markets are positioned to capture disproportionate share as infrastructure investment continues.
Market Impact: Cuts EDTA volume 3 to 5%

Food Safety Regulation Expands Preservative-Grade Adoption

Food safety regulators across several emerging markets have expanded preservative-grade sequestrant approval specifically to extend shelf life and prevent oxidative spoilage in packaged food products, directing manufacturer purchasing toward certified food-grade chelating agents on a scheduled multi-year basis. This regulatory-driven demand creates a reasonably predictable pipeline that food manufacturers can plan around regardless of broader commodity price conditions, since food safety compliance timelines carry regulatory deadlines for adoption. Producers with established food-grade certification are positioned to capture this demand ahead of newer entrants still completing qualification. Government subsidy programs typically carry multi-year budget commitments.
Market Impact: Swings margin 3 to 6 points

Market Restraints and Challenges

Regulatory Restrictions on Persistent Chelating Agents Limit Growth

Regulatory authorities across the European Union and several other jurisdictions have tightened restrictions on EDTA and other persistent, poorly biodegradable chelating agents given documented environmental accumulation concerns in wastewater systems. The root cause is genuine scientific evidence of EDTA's limited biodegradability and its capacity to remobilise heavy metals in aquatic environments once discharged. Producers are responding by accelerating biodegradable chelate reformulation programs and by phasing out EDTA-only product lines in the most heavily regulated jurisdictions. Larger producers with diversified biodegradable portfolios manage this transition more effectively than smaller EDTA-only competitors.
Market Impact: Adds USD 68 million in demand

Feedstock Price Volatility Complicates Margin Planning

Amino acid and phosphate feedstock prices fluctuate meaningfully with agricultural commodity and phosphate rock mining conditions, creating margin pressure that fixed industrial contracts often cannot fully absorb during periods of sustained feedstock cost increases. The root cause is sequestrant producers' direct exposure to agricultural and mining commodity markets that move independently of chemical demand or manufacturing activity. Producers are responding by negotiating feedstock price escalation clauses into longer-term industrial contracts and by increasing forward purchasing to smooth cost volatility across delivery periods. Larger producers with diversified feedstock purchasing manage this exposure more effectively than smaller regional competitors.
Market Impact: Lifts pharmaceutical-grade demand 18%
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows end-use application, the single commercial logic determining purity requirement, regulatory pathway, and buyer relationship structure across the category. Food preservation dominates by volume, while pharmaceutical and personal care grades grow fastest on formulation investment. Buyers increasingly evaluate suppliers against this same application lens throughout qualification and renewal. That lens shapes procurement decisions broadly.
sequestrants-market-report-trends-market-share-analysis-1787594607641

Pharmaceutical and Healthcare

Pharmaceutical and healthcare applications grow fastest at 8.8%, about 1.57 times the overall 5.6% rate, as drug stabilization and metal detoxification therapy formulators specify high-purity chelating agents that industrial-grade sequestrants were never designed to satisfy at pharmacopoeia documentation standards. This segment reaches an entirely different buyer base than traditional detergent and food customers, spanning pharmaceutical manufacturers and clinical formulation teams investing at a pace industrial chemical demand rarely matches. Producers with dedicated pharmaceutical-grade purification capacity are capturing this demand fastest, since retooling standard production for pharmacopoeia-grade tolerances requires meaningful capital investment most industrial-focused producers have not committed to. Suppliers serving this segment increasingly need dedicated trace-metal testing entirely distinct from standard industrial-grade qualification.
CAGR 8.8%

Personal Care and Cosmetics

Personal care and cosmetics applications grow second-fastest at 7.5%, driven by formulators seeking metal ion stabilization for shampoos, lotions, and skincare products requiring documented skin compatibility and biodegradability credentials increasingly demanded by clean-label consumers. This segment has proven particularly valuable as personal care brands increasingly favour biodegradable chelating agents over traditional EDTA given tightening ingredient sourcing policies at major retailers. Manufacturers increasingly combine sequestrant sourcing decisions with broader clean-label ingredient portfolio strategy rather than treating it as a standalone commodity purchase. Producers here compete on biodegradability documentation and formulation compatibility given the specification requirements these products demand. Regulatory scrutiny on ingredient sourcing continues intensifying across major consumer markets, reinforcing this shift further.
CAGR 7.5%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Western Europe leads on its deep specialty chelating agent production heritage, North America follows on water treatment and industrial descaling demand, and South Asia and Pacific posts the fastest regional growth. off a considerably smaller existing base than either Western Europe or North America offer today.

North America

Water treatment and industrial descaling demand, rather than pure detergent volume, explain North America's 23% share and its 5.8% growth, anchored by Dow and Lonza facilities serving both established municipal water treatment customers and rapidly growing pharmaceutical-grade manufacturers. American water utilities increasingly specify sequestrant-based descaling programs given the operational continuity advantage this represents over mechanical alternatives. Pharmaceutical-grade demand adds a second major growth vector here as domestic drug manufacturing continues expanding. Growth here should keep tracking water treatment and specialty grade adoption more than any independent detergent consumption cycle. Retail and industrial distribution partnerships also continue expanding the category's reach into smaller manufacturers. Domestic reshoring incentives continue reinforcing this specialty investment trend.
Share: 23% | CAGR: 5.8% (2026 to 2036)

Western Europe

Deep specialty chelating agent production heritage explains Western Europe's 26% share, the largest of any region, anchored by Nouryon and BASF facilities with decades of chelation chemistry expertise and detergent manufacturer relationships across the continent. European regulators have driven the industry's fastest biodegradable chelate transition given the region's leading restrictions on persistent chelating agents. Growth of 4.0%, the slowest of any region, reflects this regulatory-constrained EDTA decline directly even as biodegradable grades continue expanding. Regional producers maintain substantial technical service capacity despite the slower growth outlook. Regional producers increasingly redirect capacity toward export markets given the domestic regulatory-constrained demand outlook. That trend should keep reshaping regional producer investment priorities going forward.
Share: 26% | CAGR: 4.0% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
sequestrants-market-report-trends-country-cagr-analysis-1787594608151

Where Producers Can Defend Category Margin

EDTA-based volume sets a real ceiling on legacy growth in this market, but four commercial moves let producers capture more value above that ceiling regardless of chemistry, and regardless of how quickly biodegradable and pharmaceutical-grade demand ultimately reshapes overall category revenue mix across the coming decade of regulatory transition. Each requires distinct investment well ahead of visible demand.

Build biodegradable chelate chemistry capability early

Producers investing in biodegradable chelate chemistry ahead of broader industry recognition of regulatory transition's commercial scale capture detergent and personal care contracts that EDTA-only producers cannot service at required biodegradability specification. This investment requires meaningful research expenditure distinct from standard EDTA production, but biodegradable material already commands premiums of 25% to 35% over EDTA-grade pricing, and early movers are securing multi-year manufacturer relationships that later entrants find considerably harder to displace once qualified. Manufacturers increasingly favour suppliers who can demonstrate proven biodegradability performance across a range of formulations rather than laboratory results alone.
Market Impact: Captures a 25% to 35% price premium now

Secure pharmacopoeia certification quickly early on

Producers securing pharmacopoeia-grade certification across multiple national regulatory jurisdictions capture pharmaceutical contracts that uncertified competitors cannot bid on given the documentation and traceability requirements involved. This investment requires sustained regulatory affairs and quality system investment distinct from standard industrial-grade qualification, but it opens access to a growing, higher-margin demand pipeline that pharmaceutical manufacturers increasingly prefer sourcing domestically, expanding a producer's addressable contract base by roughly 7 to 10 percentage points. Manufacturers increasingly treat certification breadth as a baseline qualification requirement rather than a differentiator once several competitors have secured it.
Market Impact: Expands addressable contracts by 7 to 10 points

Expand food-grade certification programs broadly now

Producers securing food-grade certification across multiple emerging market regulatory jurisdictions are winning specification wins that uncertified competitors increasingly cannot match given tightening food safety requirements. This certification requires dedicated quality control investment spanning one to two years, but it directly addresses a specification preference shift that shows every sign of accelerating rather than reversing across major food manufacturer customers. Food manufacturers increasingly request documented certification evidence before finalising annual purchase agreements with any single supplier. Retailers increasingly favour certified suppliers over uncertified competitors during annual category planning. Manufacturers documenting a 20% improvement in food-grade sourcing compliance are winning premium contracts.
Market Impact: Wins about 18% more food contracts today outright

Lock long-term feedstock supply contracts with escalation terms

Producers negotiating long-term amino acid and phosphate feedstock contracts with defined price escalation terms tied to industrial contract pricing reduce margin exposure to spot-market feedstock volatility that smaller regional competitors absorb directly. This approach requires sustained procurement relationship investment with major feedstock suppliers, but producers with these arrangements in place have maintained more stable margins through the past several feedstock price cycles than competitors purchasing on spot terms. Producers securing 3 to 5 year fixed-escalation deals report steadier margins than spot-market peers across recent cycles. Producers securing multi-year cooperative deals report steadier margins than spot-market peers.
Market Impact: Stabilises margin within 3 to 5 points now

Who Controls the Margin Pool

Concentration is moderate at a CR5 of 46%, measured consistently across all participants on sequestrant and chelating agent revenue. Nouryon and BASF SE lead on chelation chemistry expertise and integrated production scale respectively, and the gap to Dow and other established challengers reflects decades of regulatory affairs and technical service investment rather than any single production advantage a challenger cannot eventually close given sufficient capital commitment. Neither leader has ceded ground to challengers so far.
Competitive activity today runs along three lines: biodegradable chelate chemistry investment targeting regulatory transition, pharmacopoeia-grade certification expansion targeting pharmaceutical demand, and food-grade certification expansion targeting emerging market food safety requirements. Smaller regional producers lacking certification breadth increasingly pursue distribution partnerships with established majors rather than building independent regulatory approval pathways from scratch given the capital and time required.

Pressure is building from Asian producers expanding biodegradable chelate export capacity specifically to challenge established Western incumbents on delivered cost, while pharmaceutical-grade demand reshapes where established majors direct new purification investment. Any producer still relying purely on commodity EDTA-based volume without biodegradable or pharmaceutical-grade diversification faces a widening growth disadvantage that production scale alone cannot offset indefinitely. Rankings should shift meaningfully over the next several years.
sequestrants-market-report-trends-company-positioning-matrix-1787594608671

Competitive Moat and Risk Dimensions

NOURYON

Moat: Deep chelation chemistry expertise

Nouryon holds the deepest chelation chemistry research capability in the entire category, built over decades of specialty chemical development inherited from its AkzoNobel heritage. Its established biodegradable chelate portfolio also gives it a regulatory transition head start that newer entrants cannot replicate quickly. That head start also lets it capture reformulation contracts before regulatory deadlines force competitor action.
NOURYON

Risk: Concentrated European regulatory exposure

Nouryon's production and revenue remain heavily concentrated in European markets specifically, exposing it more directly to the region's tightening chelating agent regulation than more geographically diversified competitors positioned in less-regulated markets. A prolonged expansion of biodegradable-only mandates would weigh more heavily on Nouryon's remaining EDTA business than on diversified rivals.
BASF SE

Moat: Integrated production and technical scale

BASF operates integrated sequestrant production connected to its broader specialty chemicals portfolio, giving it manufacturing scale and technical resources smaller specialty competitors cannot match. Its diversified customer base across detergent, food, and pharmaceutical categories also reduces its exposure to any single segment's demand cycle. That reach also lets it bundle products across applications within a single account relationship.
BASF SE

Risk: Complex portfolio dilutes focus

BASF's breadth across dozens of specialty chemical categories beyond sequestrants means this specific segment receives less dedicated management attention than at smaller, category-focused competitors. This could slow its response to fast-moving trends like biodegradable transition relative to more specialized rivals. Competitors with sharper category focus can move faster on emerging biodegradable opportunities.

Players Tracked

Prominent Players

Nouryon
BASF SE
Dow Inc
Lonza Group
Innophos Holdings

Other Key Players

Solvay SA
Kemira Oyj
ADOB Sp. z o.o.
Jungbunzlauer Holding
Cargill Incorporated
Prayon Group
ICL Group
Merck KGaA
Yara International
Nagase and Co
Zhejiang Wanshida Chemical
Shandong Tiancheng Chemical
Bartek Ingredients
Tate and Lyle
Akzo Nobel N.V.

Recent Developments

FEBRUARY 2025

Nouryon expands biodegradable chelate production capacity

Nouryon completed a capacity expansion at a biodegradable chelate production facility, adding GLDA production lines ahead of rising regulatory-driven demand. The project was an organic capacity expansion funded internally, not an acquisition or joint venture, targeting detergent manufacturer customers specifically. Production ramp-up completes within twelve months.
Signal: Established producers keep investing directly in biodegradable capacity rather than defending EDTA volume alone. That confidence signals regulatory demand strength.
OCTOBER 2024

BASF signs detergent manufacturer supply agreement

BASF SE signed a multi-year supply agreement with a major detergent manufacturer covering biodegradable chelating agent volume across several product lines. The arrangement was a commercial supply contract, including formulation support commitments. Analysts view the deal as confirmation of accelerating biodegradable reformulation investment. Terms span the full contract period.
Signal: Detergent manufacturers increasingly value integrated formulation support alongside supply. Long-term formulation partnerships increasingly matter more than spot supply here.
JUNE 2025

Innophos Holdings acquires pharmaceutical-grade chelate producer

Innophos Holdings acquired a smaller pharmaceutical-grade chelate producer outright, a genuine acquisition rather than a joint venture or minority stake, adding high-purity purification capability to its specialty chemical portfolio. The purchase strengthens Innophos Holdings's upstream purification capability considerably. Terms of the transaction were not disclosed publicly.
Signal: Major specialty chemical companies buy purification technology rather than building it internally. Build versus buy favours buying.

Amino Acid and Phosphate Feedstock Cost

Amino acid and phosphate feedstock runs 42% of cost of goods sold across sequestrant producers, sourced either through integrated agricultural processing operations or purchased separately from feedstock suppliers under annual or multi-year contracts. Chelation synthesis, purification, and quality testing add a further 24% to 30%, with packaging and logistics making up much of the remainder.
The 2022 agricultural commodity price spike showed how directly that exposure translates into margin. Global amino acid feedstock prices climbed sharply that year as fertiliser cost increases and supply chain disruption affected major agricultural producing regions simultaneously, and industry trade data recorded sequestrant feedstock costs climbing meaningfully across the period. Producers without diversified feedstock sourcing absorbed a disproportionate share of that increase given competition with broader agricultural buyers for the same supply.

Exposure separates producers cleanly by sourcing scale and diversification. Larger incumbents with diversified supplier relationships across multiple feedstock sources absorbed that shock more effectively than smaller specialty producers dependent on narrower supplier relationships. That gap has hardened into a durable disadvantage for smaller producers without the purchasing scale to negotiate favourable long-term feedstock contracts. Smaller producers increasingly seek cooperative purchasing arrangements to approximate that scale advantage.
sequestrants-market-report-trends-cost-volatility-analysis-1787594608867

Diversify amino acid and phosphate feedstock sourcing

Producers sourcing amino acid and phosphate feedstock from multiple suppliers and geographies reduce exposure to localized supply disruption or price spikes in any single source. This diversification requires additional supplier relationship management but has proven valuable during recent feedstock price volatility affecting broader agricultural markets simultaneously. Producers without this diversification absorb more volatility. This requires additional supplier relationship management overall.

Secure long-dated feedstock supply contracts

Locking multi-year amino acid and phosphate feedstock pricing and volume commitments removes much of the spot-market volatility that follows any single supply disruption. This approach has become increasingly standard among larger sequestrant producers with the purchasing scale to negotiate favourable forward terms with feedstock suppliers. This approach also reduces reliance on any single supplier's production schedule or logistics network.

Shift product mix toward higher-margin specialty grades

Producers with greater pharmaceutical and personal care-grade revenue share are less exposed to feedstock volatility relative to revenue, since premium specialty-grade pricing carries more room to absorb input cost increases than thin-margin EDTA-grade sales. This mix shift provides a genuine cushion during periods of sustained feedstock cost pressure. Investors reward this mix discipline with favourable multiples.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with real margin separation tied to biodegradability and purity requirement rather than raw feedstock cost alone. Standard EDTA-based sequestrants compete largely on delivered cost against benchmark pricing, while biodegradable and pharmaceutical-grade products earn meaningfully more on formulation science and purity documentation that commodity-grade producers cannot easily replicate. Buyers increasingly specify tier explicitly during supplier qualification rather than treating sequestrants as one undifferentiated commodity chemical.
The tension between EDTA volume and specialty premium runs through every producer's capacity allocation decision each year. EDTA-based volume still represents a meaningful share of the market by tonnage despite regulatory-constrained growth, yet margin and growth increasingly concentrate in biodegradable and pharmaceutical grades that require formulation investment most EDTA-only producers have not built. That formulation gap, more than any difference in underlying chelation chemistry, is what separates the tiers most sharply today.

High-value pools concentrate specifically where technical or regulatory requirements limit substitutable supply: pharmaceutical-grade formulations commanding the strictest purity performance premiums, and biodegradable grades rewarding producers who invested in reformulation years ahead of any specific regulatory deadline. That gap should keep widening as reformulation investment compounds across the forecast period.

Volume / Commodity-Adjacent Tier

Standard EDTA-based sequestrants sold largely on delivered cost against benchmark pricing across major established detergent and food manufacturer relationships. Producers here compete almost entirely on delivered cost and reliability of supply rather than technical differentiation.
Gross Margin: 14-20%

Premium / Certified Tier

Food-grade and personal care formulations commanding real premiums for biodegradability documentation and proven manufacturer performance history. Buyers in this tier require documented performance history before committing to any long-term contract.
Gross Margin: 24-32%

Sustainability / Regulatory / Next-Generation Tier

Pharmaceutical-grade and biodegradable chelate formulations meeting emerging purity performance and traceable sourcing requirements that mass-market production was never designed to satisfy. Buyers here increasingly demand full sourcing transparency before finalising any supply relationship.
Gross Margin: 30-40%
sequestrants-market-report-trends-portfolio-architecture-1787594609371

High-value Sub-segments and Strategic Watch-out

Pharmaceutical and Healthcare

High value and the fastest-growing segment at 8.8% CAGR, anchored by drug formulators reaching an entirely different buyer base than traditional detergent customers. Premiums of 25% to 35% reflect genuine purity purification cost rather than brand positioning alone. Manufacturer relationships stay sticky once qualified. Buyers rarely revisit qualification.
Gross Margin: 30-38%

Personal Care and Cosmetics

High value with strong second-fastest growth at 7.5%, driven by biodegradability demand among formulators requiring clean-label documentation. Supply remains constrained by biodegradable chemistry expertise that generic industrial-grade producers lack, sustaining real pricing power. Buyers rarely switch suppliers once a formulation is validated and proven reliable.
Gross Margin: 24-32%

Standard EDTA-Based Grades

The volume core of the market despite regulatory-constrained growth, competing on delivered cost against benchmark pricing with thin margins and intense producer rivalry. Growth tracks a well-documented regulatory decline cycle with limited differentiation between suppliers. Producers here increasingly diversify into higher-margin formats to offset this segment's constrained growth.
Gross Margin: 14-20%

EDTA-Only Legacy Producers

The strategic watch-out. Producers dependent purely on EDTA-grade volume without biodegradable or pharmaceutical-grade investment face a widening exposure to regulatory restriction and competitive substitution risk over the coming decade. These producers face a widening competitive gap against diversified rivals over the next several years. Buyers avoid these producers during qualification.
Gross Margin: 6-12%

Regulatory Cycles and Manufacturer Loyalty

Demand here runs on multi-year manufacturer reformulation and supply contracts rather than transactional sales for the majority of branded volume, since detergent, food, and pharmaceutical manufacturers need consistent, regulatory-compliant chelating agent performance locked in well before any product reformulation launches. Contract renewal typically follows product reformulation cycles spanning several years rather than the annual transactional purchasing common in commodity chemical sales.
Adoption depth varies sharply by application. Pharmaceutical and personal care buyers show the strongest supplier loyalty given formulation validation cost and the operational risk of switching mid-product-cycle, while detergent manufacturers switch relatively freely based on price and delivery lead time given the category's mature, standardised production processes. Food-grade buyers sit between the two, valuing documentation consistency over transactional pricing given regulatory scrutiny considerations.

Buyer profiles have shifted generationally as chelating agent procurement moved from purely cost-driven industrial purchasing toward regulatory-driven, technically demanding qualification programs spanning multiple application categories simultaneously. Younger procurement teams increasingly evaluate biodegradability documentation and supply reliability rather than upfront chemical price alone, a shift that favours producers investing in formulation and certification depth over those competing purely on traditional commodity volume.
sequestrants-market-report-trends-end-use-penetration-index-1787594609858

Where Formulation Investment Decides Outcomes

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / BIODEGRADABLE CHEMISTRY INVESTMENT

Early formulation capability will keep capturing the fastest-growing regulatory shift

Producers investing in biodegradable chelate chemistry are capturing detergent and personal care contracts that EDTA-only producers cannot service at required biodegradability specification, and that gap will not close quickly given the research investment involved, since manufacturers rarely switch suppliers once a formulation is validated against a specific regulatory deadline. Expect continued investment concentrating among producers who committed to this capability years ahead of the segment's current growth, leaving later entrants a steeper reformulation curve to climb. Later entrants face a considerably steeper qualification curve to catch up.
02 / EDTA VOLUME DIVERSIFICATION

Diversified producers will outperform EDTA-only legacy competitors

EDTA-based volume growth is constrained by a well-documented, tightening regulatory cycle, and producers dependent purely on EDTA-grade production face a steadily shrinking addressable market regardless of how well they execute operationally. Companies that diversified into biodegradable and pharmaceutical formats early have already begun offsetting EDTA volume loss with faster-growing revenue streams. Expect continued consolidation toward diversified producers as EDTA-only producers face an increasingly difficult commercial position that should keep widening,, one later entrants will find considerably harder to reverse as the trend visibly continues.
03 / PHARMACEUTICAL CERTIFICATION EXPANSION

Early certification will outcompete uncertified regional incumbents

Pharmaceutical excipient sourcing requirements will keep tightening across additional regulatory jurisdictions, and producers who secured certification ahead of that tightening are already winning contracts citing proven compliance track record specifically, since certified capacity remains scarce relative to growing pharmaceutical demand. That scarcity sustains real advantage for early movers who invested ahead of the requirement. Expect broader industry investment in certification to eventually compress this advantage as more producers complete qualification, with buyers increasingly treating this credential as a baseline requirement rather than a differentiator.
04 / EMERGING MARKET APPROVAL

Early emerging market approval will build durable first-mover advantage

China and India's expanding food safety regulation and rising urban middle-class demand represent the single largest incremental growth opportunity in this market, and producers investing in food-grade certification now are building market access that later entrants must wait years to replicate given typical regulatory review timelines. This opportunity depends on genuine regulatory affairs investment rather than simple product export. Expect continued investment concentrating specifically in these markets as regulatory approval advances, with later movers finding market entry considerably more costly once approval clears.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Sequestrants Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Sequestrants Exposure Evaluation 2025-26
CLIENT PROFILE
A regional detergent manufacturer distributing across Western European retail markets approached MMA while planning a mandatory reformulation away from EDTA-based chelating agents. The client reported annual detergent category revenue near USD 180 million, with limited prior experience formulating biodegradable chelate alternatives at commercial scale (client-reported, unverified by MMA). The manufacturer had never previously worked with a specialty biodegradable chelate supplier directly.
STRATEGIC CHALLENGE
Management wanted to complete its EDTA phase-out ahead of tightening regulatory deadlines, but lacked internal expertise comparing biodegradable chelate performance against its existing formulation requirements. The product development team wanted to move quickly, while quality worried that rushing reformulation without adequate testing could result in reduced cleaning performance reaching retail shelves.
MMA APPROACH
MMA benchmarked available biodegradable chelating agent suppliers against the client's specific performance and regulatory documentation requirements, then modelled the reformulation and testing timeline needed for a credible product transition. We also assessed regulatory deadline requirements across the client's markets to identify the fastest viable path to compliance. Findings were delivered ahead of the client's board budget approval deadline.
KEY FINDINGS
  1. The client's initial reformulation timeline assumptions underestimated the performance testing required for biodegradable substitution considerably (client-reported, unverified by MMA). Additional stability trials were required before the client felt confident proceeding.
  2. A qualified biodegradable chelate supplier with existing detergent formulation experience could compress the client's reformulation timeline meaningfully compared with developing proprietary technology internally.
  3. Regulatory documentation requirements for the biodegradability claim required more extensive testing than the client's compliance team had originally planned for. This documentation gap materially influenced the client's final formulation and testing decisions.
  4. A phased product line transition reduced execution risk considerably compared with the simultaneous full-portfolio reformulation originally proposed. This phased approach also allowed the marketing team to refine messaging before wider rollout.
CLIENT PROFILE
A regional detergent manufacturer distributing across Western European retail markets approached MMA while planning a mandatory reformulation away from EDTA-based chelating agents. The client reported annual detergent category revenue near USD 180 million, with limited prior experience formulating biodegradable chelate alternatives at commercial scale (client-reported, unverified by MMA). The manufacturer had never previously worked with a specialty biodegradable chelate supplier directly.
STRATEGIC CHALLENGE
Management wanted to complete its EDTA phase-out ahead of tightening regulatory deadlines, but lacked internal expertise comparing biodegradable chelate performance against its existing formulation requirements. The product development team wanted to move quickly, while quality worried that rushing reformulation without adequate testing could result in reduced cleaning performance reaching retail shelves.
MMA APPROACH
MMA benchmarked available biodegradable chelating agent suppliers against the client's specific performance and regulatory documentation requirements, then modelled the reformulation and testing timeline needed for a credible product transition. We also assessed regulatory deadline requirements across the client's markets to identify the fastest viable path to compliance. Findings were delivered ahead of the client's board budget approval deadline.
KEY FINDINGS
  1. The client's initial reformulation timeline assumptions underestimated the performance testing required for biodegradable substitution considerably (client-reported, unverified by MMA). Additional stability trials were required before the client felt confident proceeding.
  2. A qualified biodegradable chelate supplier with existing detergent formulation experience could compress the client's reformulation timeline meaningfully compared with developing proprietary technology internally.
  3. Regulatory documentation requirements for the biodegradability claim required more extensive testing than the client's compliance team had originally planned for. This documentation gap materially influenced the client's final formulation and testing decisions.
  4. A phased product line transition reduced execution risk considerably compared with the simultaneous full-portfolio reformulation originally proposed. This phased approach also allowed the marketing team to refine messaging before wider rollout.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 5 months): Qualify a biodegradable chelate supplier and complete performance testing for the priority product line. Phase 2: Phase 2 (5 to 11 months): Transition the priority line while completing full biodegradability documentation. Marketing tracked consumer response closely throughout this test period. Phase 3: Phase 3 (11 to 20 months): Complete remaining portfolio transition ahead of the final regulatory deadline. Distribution partners were briefed well ahead of the multi-market rollout date.
OUTCOME
The client completed its EDTA phase-out within the regulatory deadline following the phased approach, avoiding the performance degradation risk a faster rollout would likely have caused. The transition also secured a reported retail listing renewal worth USD 7 million in projected annual volume (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Sequestrants Market?

The sequestrants market reached USD 3.6 billion in 2025, covering food preservation, water treatment, detergent, personal care, pharmaceutical, and agricultural applications globally. Growth spans multiple end-use categories.

How large will the Sequestrants Market be by 2036?

The market is projected to reach USD 6.55 billion by 2036 under the base case scenario, representing a 1.72 times expansion over the 2026 starting value.

What is the CAGR for the Sequestrants Market 2026 to 2036?

The base case CAGR is 5.6%, with a bull case of 6.8% and a bear case of 4.3%. Biodegradable chelate adoption and regulatory restriction drive most of the variance.

Which segment is growing fastest?

Pharmaceutical and healthcare applications grow fastest at 8.8% CAGR, about 1.57 times the overall market rate. Drug stabilization formulators reaching new buyer segments drive this growth directly.

Who are the major companies in the Sequestrants Market?

Leading companies include Nouryon, BASF SE, Dow Inc, Lonza Group, and Innophos Holdings, holding roughly 46% combined market share. These five compete on chelation chemistry expertise and integrated production scale.

Which country is growing fastest?

India posts the fastest national growth at 8.2% CAGR, driven by rising food safety regulation and expanding water treatment investment. Growing manufacturing investment anchors most of this growth.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Application

  • Food and Beverage Preservation
  • Water Treatment and Industrial Descaling
  • Detergents and Household Cleaning
  • Personal Care and Cosmetics
  • Pharmaceutical and Healthcare
  • Agricultural Micronutrient Chelates

By End-Use Industry

  • Food and Beverage Manufacturing
  • Water and Wastewater Treatment
  • Household and Institutional Cleaning
  • Personal Care Manufacturing
  • Pharmaceutical Manufacturing

By Commercial Dimension

  • Direct Producer Supply
  • Distributor and Trader Channel
  • Long-Term Manufacturer Contracts
  • Spot Market Sales

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
This market comprises sequestrants and chelating agents used in food and beverage preservation, water treatment, detergents, personal care, pharmaceutical, and agricultural micronutrient applications. Unrelated metal complexing catalysts sold for industrial polymerisation processes are excluded from this scope.
Quantitative Units
USD billions (current prices); metric tonnes of sequestrant volume where applicable
Segmentation Dimensions
By Application; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Nouryon, BASF SE, Dow Inc, Lonza Group, Innophos Holdings, Solvay SA, Kemira Oyj, ADOB Sp. z o.o., Jungbunzlauer Holding, Cargill Incorporated, Prayon Group, ICL Group, Merck KGaA, Yara International, Nagase and Co, Zhejiang Wanshida Chemical, Shandong Tiancheng Chemical, Bartek Ingredients, Tate and Lyle, Akzo Nobel N.V.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-CHM-104
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Sequestrants Market Report (2026 to 2036).

The full MMA Sequestrants report sizes the market across six application segments, five end-use industries, four commercial channels, and seven regions through 2036. It profiles twenty companies on a consistent basis of sequestrant and chelating agent revenue, scoring each on biodegradable chemistry depth, pharmacopoeia certification breadth, and food-grade qualification. Scenario models quantify how biodegradable chelate adoption, regulatory restriction, and pharmaceutical demand growth move both demand and realised pricing. The report also includes delivered-cost modelling by feedstock base, an EDTA-only exposure screen, and pharmaceutical segment economics built for procurement, strategy, and investment teams.
Six-segment application demand breakdown detail view
Feedstock delivered-cost bridge model overview detail
EDTA-only exposure screening framework overview detail
Producer formulation depth benchmarking review detail
Pharmaceutical segment economics deep detail review
Regional regulatory transition mapping review detail

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts